Send to

Choose Destination
F1000Res. 2018 Aug 1;7. pii: F1000 Faculty Rev-1170. doi: 10.12688/f1000research.14874.1. eCollection 2018.

Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination.

Author information

Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.


Malaria remains a significant contributor to global human mortality, and roughly half the world's population is at risk for infection with Plasmodium spp. parasites. Aggressive control measures have reduced the global prevalence of malaria significantly over the past decade. However, resistance to available antimalarials continues to spread, including resistance to the widely used artemisinin-based combination therapies. Novel antimalarial compounds and therapeutic targets are greatly needed. This review will briefly discuss several promising current antimalarial development projects, including artefenomel, ferroquine, cipargamin, SJ733, KAF156, MMV048, and tafenoquine. In addition, we describe recent large-scale genetic and resistance screens that have been instrumental in target discovery. Finally, we highlight new antimalarial targets, which include essential transporters and proteases. These emerging antimalarial compounds and therapeutic targets have the potential to overcome multi-drug resistance in ongoing efforts toward malaria elimination.


Plasmodium; antimalarial; drug discovery; drug targets; resistance

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central
Loading ...
Support Center